Consider signing up for Family Health Research, a newsletter designed to promote the use of evidence-based practices in reproductive health programs.

Each issue examines a key topic in reproductive health care – The current issue of the newsletter describes efforts to develop a safe, effective, and acceptable vaginal microbicide to prevent HIV. You will find it at: http://www.fhi360.org/resource/effectiveness-and-safety-tenofovir-gel-antiretroviral-microbicide-prevention-hiv-infectio-0

The newsletter is published by Family Health International. Together with its partners, it is working with women throughout the world to test a variety of candidate microbicides, including antiretroviral-based products such as tenofovir gel.

Women have an especially high risk of HIV infection because of biologic susceptibility, economic dependence on their male partners, and difficulties negotiating condom use in their sexual relationships. A method of HIV prevention that a woman could control, such as a vaginal microbicide, could help overcome some of these disparities and save many lives.

To order a hard copy of the issue, please send a request to This email address is being protected from spambots. You need JavaScript enabled to view it..